Mesoblast Financial Results and Corporate Update Webcast
November 21, 2022 06:00 ET
|
Mesoblast Limited
NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022
October 30, 2022 19:50 ET
|
Mesoblast Limited
NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD
October 02, 2022 19:52 ET
|
Mesoblast Limited
NEW YORK, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that it has submitted...
Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022
August 30, 2022 19:05 ET
|
Mesoblast Limited
At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 Up to an additional US$40...
Mesoblast Corporate Update and Financial Results Webcast
August 29, 2022 20:14 ET
|
Mesoblast Limited
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Jane Bell Joins Mesoblast Board
August 18, 2022 07:00 ET
|
Mesoblast Limited
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed...
Appendix 4C Quarterly Activity Report
July 29, 2022 07:05 ET
|
Mesoblast Limited
NEW YORK, July 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
July 11, 2022 20:40 ET
|
Mesoblast Limited
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L,...
Mesoblast Key Opinion Leader Event Series for Investors & Analysts
June 09, 2022 07:00 ET
|
Mesoblast Limited
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the...
Operational Highlights and Financial Results for the Period Ended March 31, 2022
May 31, 2022 20:15 ET
|
Mesoblast Limited
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...